This is an Open Access article licensed under the terms of the Creative Commons AttributionNonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only. The aim of this study was to evaluate the miRNAs involvement in gestational diabetes mellitus (GDM), a well known risk factor for fetal overgrowth. Methods: Differential microRNA expression in placental tissues of normal controls and women with GDM were identified by miRNA micorarray analysis and further confirmed by quantitative real-time PCR (qRT-PCR) on an independent set of normal and GDM placental tissues. Target genes of microRNAs were bioinformatically predicted and verified in vitro by Western blotting. Results: Our results uncovered 9 miRNAs that were significantly deregulated in GDM samples: miR-508-3p was up-regulated and miR-27a, miR-9, miR-137, miR-92a, miR-33a, miR-30d, miR-362-5p and miR-502-5p were down-regulated. Bioinformatic approaches revealed that the microRNAs signature identifies gene targets involved in EGFR (epidermal growth factor receptor)-PI3K (phosphoinositide 3-Kinase)-Akt (also known as protein kinase B) pathway, a signal cascade which plays important roles in placental development and fetal growth. We found that the protein levels of EGFR, PI3K and phospho-Akt were up-regulated and PIKfyve (a FYVE fingercontaining phosphoinositide kinase), a negative regulator of EGFR signaling, was downregulated significantly in GDM tissues. We also confirmed PIKfyve was a direct target of miR-508-3p. Conclusion: Our data identified a miRNA signature involvement in GDM which may contribute to macrosomia through enhancing EGFR signaling.
Introduction
Gestational diabetes mellitus (GDM) is defined as any degree of glucose intolerance that is first detected during pregnancy. GDM is a risk factor for pregnancy-related maternal and fetal morbidity. Babies born to mothers with GDM are typically at increased risk of excessive birth weight or macrosomia. A macrosomic foetus is defined as weighing more than 4 kg. Moreover, macrosomic babies are prone to developing childhood obesity and type 2 diabetes and/or cardiovascular diseases in the later stage of life [1] [2] [3] .
Growth factors within the maternal circulation, such as insulin-like growth factors 1 and 2 (IGF1 and IGF2), epidermal growth factor (EGF) and platelet-derived growth factor (PDGF) have been shown to be important regulators of placental development and fetal growth [2] . Because these growth factors exert their effects via intracellular signaling cascades, disrupted or dysregulated growth factor signaling pathways are linked to aberrant fetal growth. The roles of EGF/EGFR signaling cascade for placental development and fetal growth have been confirmed in vitro and in vivo. Alternations of EGFR function are associated with reduced embryonic growth in humans [4] . EGFR-deficient mice had significant smaller placentas and displayed severe fetal growth restriction [5] . The results from in vitro study using human placental cell lines indicated that EGF promotes trophoblast proliferation and inhibits trophoblast apoptosis [6] . However, the detailed mechanisms by which EGFR signaling cascade is deregulated in placenta are not well known.
MicroRNA (miRNA), a small non-coding, single-stranded RNA of 20~22 nucleotides long, is recognized as one of key post-transcriptional regulators of gene expression by binding to the 3' untranslated region (UTR) of specific genes to affect mRNAs stability and/ or translation. MiRNA is involved in a variety of cellular processes, for example, proliferation, differentiation, apoptosis and development. Aberrant expression of miRNA has been detected in many diseases, such as cancer, type 2 diabetes as well as cardiovascular neurological and autoimmune diseases [7] [8] [9] [10] . Previous studies have suggested that miRNAs are involved in GDM [11] . However, the miRNA expression profiles in placenta tissues from GDM patients and its biological significance, to our knowledge, have not been evaluated.
In the present study, we compared the miRNA expression profiles of placenta samples from healthy and GDM women by microarray analysis. Nine miRNAs have been further confirmed to be significantly deregulated in GDM samples by qRT-PCR analysis. These deregulated miRNAs identify gene targets involved in EGFR/PI3K/Akt signaling cascade which plays essential roles in regulating fetal growth during pregnancy [2, 12] . Our data identify a specific miRNA signature in GDM and provide new potential insights into the mechanisms of enhanced fetal growth in GDM patients.
Materials and Methods

Patients
The subjects were recruited in the Department of Obstetrics and Gynecology, the 306 th Hospital of P.L.A, Beijing, China. This study was approved by an institutional review board, and placental tissue samples were collected after informed consent. The pregnant women were 21 to 37 years old. Placentas were obtained from 15 healthy women and 15 women with GDM immediately after delivery, frozen and kept in liquid nitrogen until RNA or protein isolation. Delivered newborns were immediately weighed after delivery. The mean birth weight of babies from GDM mothers (4042 ± 104 g) was higher than babies from healthy mothers (3368 ± 69 g) (P<0.001). Selected control women had no significant history of illness, no pregnancy-related complications. GDM was diagnosed when fasting blood glucose > 5.1 mmol/L according to the Endocrine Society criteria.
Microarray miRNA expression profiling and data analysis
Total RNA was isolated from equal amounts of placental tissue collected from normal controls and GDM patients using RecoverAllTM Total Nucleic Acid Isolation kit (Ambion) according to the manufacturer's protocol. The purities and concentrations of RNA were determined by NanoDrop ND-2000 (Thermo).
MicroRNA profiling of 10 placental samples (5 from normal controls and 5 from GDM patients) were assessed by using Agilent Human miRNA Microarray (Agilent) according to the manufacture's protocol. The chip was scanned by Agilent Microarray Scanner and images were analyzed by Feature Extraction software 10.7 (Agilent). Data were normalized by quantile algorithm, Gene Spring Software 11.0 (Agilent). Differentially expressed miRNAs were selected with p <0.05.
miRNA targets predication TargetScan (http://www.targetscan.org/) and miRanda (http://www.microrna.org/microrna) were used to predict putative miRNA targets. To minimize the number of false predication, we performed the union and intersection operator in Excel to obtain the common targets.
qRT -PCR
To validate the expression of deregulated miRNAs in an independent set of normal (n=10) and GDM (n=10) placental tissues, total RNA was extracted with TRNzol reagent (TIANGEN Biotech, Beijing, China) and reverse transcribed into cDNAs with miRNA first-strand cDNA kit (TIANGEN Biotech, Beijing, China). Quantitative real-time PCR was performed by using miRcute miRNA qPCR detection kit (TIANGEN Biotech, Beijing, China) following manufacturer's instruction. PCR reactions were conducted in 7300 Real-Time PCR System (Applied Biosystems, Foster City, CA). U6 snRNA was used as internal control for normalization. Relative expression for miRNA was determined using 2 -△△Ct method. All reactions were performed in triplicate.
For mRNA analysis, cDNA was synthesized from total RNA using RevertAid First Strand cDNA Synthesis kit (Thermo Scientific, Waltham, MA) and quantitative real-time PCR was performed by using SYBR Green qPCR Master Mix (Thermo Scientific, Waltham, MA). The cycle conditions included an initial denaturation step at 95°C for 30 seconds followed by 40 cycles of amplification for 3 seconds at 95°C and 1 minute at 60°C. The housekeeping gene GAPDH was used as an internal control. The sequences of gene specific primers used for qRT-PCR were as follows: EGFR (forward: 5'-GTT TGG GAG TTG ATG ACCTT-3'; reverse: 5'-GGA ACT TTG GGC GAC TATCT-3'), PIK3CA (forward: 5'-TGG ATG CTC TAC AGG GCTTT-3'; reverse: 5'-GTC TGG GTT CTC CCA ATTCA-3'), PIK3CB (forward: 5'-GCA TTA AAA GGG AGC GAGTG-3'; reverse: 5'-CAT GCC GTC GTA AAA TCAGA-3'), PIK3CD (forward: 5'-CTG GCT GAA GTC CAA GAACC-3'; reverse: 5'-CTC GGA TCA TGA TGT TGTCG-3'), PIK3CG (forward: 5'-ATA CCA TGA TAG CGC CCTTG-3'; reverse: 5'-AAT CACA GCG AAC CTC TGCT-3'), PIK3R2 (forward: 5'-AGA TGG GCA CTA TGG CTT CTCAG-3'; reverse: 5'-CCT CCA CGC TGT CCT CCTTG-3'), PIK3R3 (forward: 5'-GGA GGA GGT AAA TGA CAAAT-3'; reverse: 5'-CCT TCC GCA AAG TCA AAGTA-3'), Akt (forward: 5'-CTG GGC AAG GGC ACT TTCGG-3'; reverse: 5'-AGG CGG TCG TGG GTC TGGAA-3'), PIKfyve (forward: 5'-TGT AAA GAA TAC CGA AATGC-3'; reverse: 5'-TAA TCT GAT AGG GCT GCTAC-3'), GAPDH (forward: 5'-GGA GAA ACC TGC CAA GTATG-3'; reverse: 5'-TTA CTC CTT GGA GGC CAT GTAG-3').
Western blotting
Total proteins were extracted from cells or tissues by using cell lysis buffer (Cell Signaling Technology, Danvers, MA) and separated by SDS-PAGE and transferred to nitrocellulose membrane (Amersham Biosciences, Amersham, UK). After blocking, the membrane was incubated with primary antibodies overnight at 4°C followed by washing and incubation with a horseradish peroxidase-conjugated secondary antibody for 2 hours at room temperature. Bands were detected using enhanced chemiluminescence (Applygen, Beijing, China). Relative band intensity was evaluated by Image J software (NIH). Primary antibodies used in this study were as follows: rabbit anti-EGFR (#2232; CST), anti-p110-γ (#4252; CST), anti-p85-β (ab137815; Abcam), anti-Akt (Ab-308, 21055; Signalway Antibody, MD), anti-p-Akt (Ser 473, 11054; Signalway Antibody, MD), mouse anti-PIKfyve (sc-100408; Santa Cruz) and anti-β-actin (6a3; Sungene Biotech, China) antibodies.
Cell lines and transfection
HTR-8/SVneo human trophoblast cells were cultured in RPMI 1640 (HyClone, South Logan, USA) supplemented with 10% heat-inactivated fetal bovine serum (Gibco, Paisley, United Kingdom) at 37°C in a humidified 5% CO 2 incubator. HTR-8/SVneo cells were transfected with plasmids or miR-508-3p mimics, miR-508-3p inhibitor, or miRNA negative control (RiboBio, Guangzhou, China) using Lipofectamine 2000 (Invitrogen, Carsland, CA) according to manufacturer's instruction.
Dual-luciferase reporter assay
To determine whether miR-508-3p targets PIKfyve, a 274-bp fragment of PIKfyve 3'UTR containing putative binding site of miR-508-3p was amplified by PCR with primers: 5'-GCTCTAGACACAGGTGCAGTGTATTA-3' (forward) and 5'-GCTCTAGAGTTCAAGGCAGTTATCTT-3' (reverse). The amplified products were inserted into the XbaI site of pRL-TK vector (Promega, Madison, WI). The mutated pRL-TK-PIKfyve-3'UTR construct was generated with Site-Directed Mutagenesis Kit (SBS Genetech, Beijing, China). HTR-8/SVneo cells were transfected with pRL-TK-PIKfyve-3'UTR, pGL3-control along with miR negative control (NC), miR-508-3p mimics, or miR-508-3p inhibitor for 36 h. The cells were harvested, and a luciferase assay was performed using Dual-Luciferase Assay System (Promega, Madison, WI) according to manufacturer's instructions.
Statistical analysis
Data are presented as mean ± standard deviation (S.D.) of three independent experiments. Statistical comparisons were performed using SPSS 11.5. Student's t test was used to evaluate individual differences between groups and analysis of variance (ANOVA) was used for multiple comparisons. Values of p < 0.05 are considered to be statistically significant.
Results
Identification of microRNAs differentially expressed in placental tissues of GDM patients
To investigate miRNAs involvement in GDM, we applied a high-throughput human miRNA array analysis with placental tissues from 5 normal controls and 5 GDM patients. Comparative analysis of the miRNA expression arrays between normal and GDM samples identified 29 miRNAs with significant differences (p<0.05) including upregulation of 3 miRNAs and downregulation of 26 miRNAs (Fig. 1) .
The microRNAs signature identifies gene targets involved in EGFR/PI3K/Akt pathway
To investigate the biological roles of the deregulated miRNAs in GDM, we predicted the gene targets for those 29 identified miRNAs by using the programs TargetScan, (http:// www.targetscan.org/) and miRanda (http://www.microrna.org/microrna). Interestingly, we obtained 15 miRNAs that target genes involvement in EGFR/PI3K/Akt pathway ( Fig. 2A) . To validate this miRNA signature, we performed qRT-PCR confirmation experiments on an independent set of placental tissues from normal controls (n=10) and GDM patients (n=10). QRT-PCR analysis showed a statistically significant deregulation of 9 miRNAs with miR-508- Fig. 1 . Deregulated miRNAs in placental tissues of normal controls vs. women with GDM. miRNA expression profiling of terminal placental tissues from GDM (n=5) and normal control (n=5). 29 significant deregulated miRNAs in GDM patients were identified. expression. Data from Western blotting analysis indicated that miR-508-3p suppressed PIKfyve protein expression while miR-508-3p inhibitor increased PIKfyve protein levels in HTR-8 cells (Fig. 4B) . To clarify the specific binding sites, mutated pRL-TK-PIKfyve-3'UTR vectors with some nucleotides mutation in the putative seed-binding region were constructed and transfected together with miR-508-3p mimics into HTR-8 cells. Compared with wild-type vector, there was no significant influence on the luciferase activity in the cells cotransfected with vector carrying sequences mutated from 5'-AAUC-3' to 5'-CGGU-3' and miR-508-3p mimics (Fig. 4C) . Together, these results suggest that miR-508-3p directly targets PIKfyve via its 3'UTR.
Discussion
GDM is one of the most common pregnancy complications and a well known risk factor for macrosomia [14] . Dysregulated expressions of miRNAs have been shown to be potentially disease-specific and may contribute to pathologic processes [8] . However, no reported study investigates the miRNA signature in placental tissues from GDM. To identify specific miRNA signature and its biological significance in the pathobiology of GDM, we performed miRNA profiling in placental tissues from normal and GDM patients. Our combined data set, which included array-based identification followed by qRT-PCR, uncovered 9 miRNAs with significant deregulation associated with EGFR/PI3K/Akt signaling cascade. Furthermore, by qRT-PCR and western blot analysis, we have demonstrated that enhanced EGFR signaling exists in the GDM samples. Together, our results suggest these deregulated miRNAs identified here might be implicated in GDM and in part in the pathology of fetal overgrowth via EGFR/ PI3K/Akt signaling cascade.
EGF-mediated activation of the PI3K/Akt pathway has been shown to be important in promoting placenta development and fetal growth in both humans and rodents [2, 15] . EGFR-deficient mice had significantly smaller placentas and displayed severe fetal growth [5] .Cord serum EGF concentrations increase in GDM pregnancies [1] . However, EGF has been reported not to cross the placenta barrier [16] . How EGF concentrations are increased and by which the downstream signaling molecules are regulated in placenta is not wellunderstood. Here, based on the observation that 8 down-regulated miRNAs in GDM inversely correlate with EGFR/PI3K/Akt pathway-related genes and one up-regulated miRNA targets the negative regulator of EGFR, PIKfyve, we hypothesize that these deregulated miRNAs exhibit coordinated up-regulation of EGFR/PI3K/Akt signaling, thereby contributing to fetal overgrowth in GDM patients during pregnancy.
Among the miRNAs identified, we were drawn to miR-508-3p because it is the most up-regulated miRNA and predicted to target PIKfyve. PIKfyve is a FYVE-containing phosphoinositide 3-phosphate (PI3P) 5 kinase which phosphorylates phosphatidylinositol (PtdIns) 3P to PtdIns (3, 5) P2. PIKfyve operates in diverse signaling pathways and membrane trafficking events [17] . Most recently, PIKfyve has been characterized as a negative regulator of EGFR. Er,EE et al have shown that upon EGF stimulation, Akt phosphorylates and activates the kinase PIKfyve, which promotes vesicle trafficking to lysosomes. PIKfyve activation promotes EGFR degradation, suggesting that activation of PIKfyve is to be a feedback mechanism for terminating EGFR signaling and reducing receptor abundance [13] . Here, we identified that miR-508-3p was significantly up-regulated in GDM samples and miR-508-3p directly targets PIKfyve. These results indicate that upregulation of miR-508-3p suppress PIKfyve and prevents PIKfyve-mediated EGFR degradation, thereby contributing to constitutive activation of EGFR signaling in GDM patients.
Eight miRNAs including miR-27a, miR-9, miR-137, miR-92a, miR-33a, miR-30d, miR-362-5p and miR-502-5p were predicted to identify target genes involved in EGFR/PI3K/Akt pathway and to be down-regulated in GDM tissues. Therefore, there would be a coordinated up-regulation of EGFR/PI3K/Akt pathway-related genes and this was also confirmed in our study. MiR-27a has been shown to exhibit coordinated regulation of the EGFR pathway in
